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**Value of the data**•This article provides information on the construction of a vector coding for human cathepsin L-EGFP chimeras, and it describes the insert׳s sequence.•The data provide detailed information on the molecular forms of cathepsin L chimeras with enhanced green fluorescent protein that are expressed in the human colorectal carcinoma HCT116 cell line.•The article provides data on the effects of cathepsin L-EGFP expression in HCT116 cells with regard to proliferation rates and metabolic activity.

**Data**

EGFP-tagging is used to visualize transport and trafficking of cellular proteins including cysteine cathepsin proteases [@bib2]. We have shown that EGFP-tagging does not interfere with intrinsic sorting signals at the N-terminus of cysteine cathepsin proteases when the tag is attached to the C-terminus via a spacer peptide [@bib2; @bib3; @bib4]. In addition, transport to endo-lysosomal compartments and other cellular destinations is not affected by the EGFP tag [@bib2; @bib3; @bib4]. Likewise, proteolytic activity is pertained in cathepsin-EGFP chimeras expressed in mammalian cell lines [@bib2; @bib3; @bib4; @bib5; @bib6; @bib7].

We have shown that cathepsin L is sorted and mis-trafficked to the nucleus of HCT116 cells as full-length protein and in proteolytically active form [@bib1]. More specifically, nuclear cathepsin L accelerates cell cycle progression of HCT116 cells which are hyper-proliferative colorectal carcinoma cells. In this article, we demonstrate via expression of cathepsin L-EGFP chimeras the effects of enhanced protease expression promoting proliferation of HCT116 cells.

1. Experimental design, materials and methods {#s0005}
=============================================

In this article, we describe the construction of a vector encoding human cathepsin L-EGFP (hCL-EGFP) with cDNA derived from cathepsin L mRNA of human HaCaT keratinocytes upon insertion into the multiple cloning site of *p*EGFP-N1 by *NheI* and *BamHI* restriction. Here, we share the relevant sequence data of *p*hCL-EGFP. The vector is introduced through lipofection to express chimeric, EGFP-tagged cathepsin L in HCT116 cells. This colorectal carcinoma cell line was further analyzed with regard to proliferation and metabolic activity by MTT-assays upon transfection with *p*hCL-EGFP in comparison to non-transfected and *p*EGFP-N1-transfected cells. The molecular forms of protein chimeras expressed in HCT116 cells were identified by immunoblotting of whole cell lysates separated by SDS-PAGE.

1.1. RNA preparation from HaCaT cells {#s0010}
-------------------------------------

The human keratinocyte line HaCaT (Human adult low Calcium high Temperature) was provided by Prof. Dr. Petra Boukamp (Deutsches Krebsforschungszentrum DKFZ, Heidelberg, Germany) and cultured in Dulbecco׳s modified Eagle׳s Medium (DMEM; Cambrex Corp., Verviers, Belgium) supplemented with 10% fetal calf serum (FCS; Gibco™ Invitrogen GmbH, Karlsruhe, Germany). Total RNA was isolated from phosphate-buffered saline (PBS)-washed confluent HaCaT cell cultures using TRIZOL reagent (TRIZOL; Invitrogen, Karlsruhe, Germany) with subsequent chloroform and isopropanol purification. The RNA pellet was washed with 75% ethanol and finally re-suspended in 30 µl of DEPC-treated water (Ambion, Huntigdon, UK). The RNA concentration was determined by nanodrop microphotometry (Kisker, Steinfurt, Germany) before aliquots were either directly used or snap-frozen in liquid nitrogen and stored at −80 °C.

1.2. Vector construction {#s0015}
========================

Total RNA at a concentration of 0.05 µg/µL was reverse transcribed with a cDNA cycle kit (Invitrogen, Karlsruhe, Germany) using oligo dT primers and AMV reverse transcriptase. Amplification of the complete cathepsin L coding sequence was by PCR with 500 ng cDNA using 0.5 µM each of the primers "CL for *NheI*" (5′-aca cag gtt tta aaa cat gaa tcc tac a-3′) and "CL rev *BamHI*" (5′-agc tac ccc act gtg tga gct ggt gga-3′), 0.125 mM each of dNTPs, and 0.4 U Phusion DNA polymerase (Finnzymes, Espoo, Finland). By this cloning strategy, restriction sites for *NheI* and *BamHI* were introduced and the stop codon was removed, thus eventually yielding the sequence for a chimeric protein with the full-length cathepsin L sequence covalently connected to the EGFP tag by a spacer peptide linker. The final PCR product and *pEGFP*-N1 plasmid were each digested with *NheI* and *BamHI* (both, MBI, St. Leon-Rot, Germany). The restricted cDNA was ligated into the linearized vector using T4-DNA ligase (MBI) in the presence of ATP-containing reaction buffer (MBI) at 4 °C overnight, followed by ligase inactivation at 65 °C for 10 min. The ligated plasmids were transformed into competent *E. coli* JM 109, and kanamycin-resistant clones were used for isolation of vector cDNA (Qiagen, Hilden, Germany), which was eluted and stored in 10 mM Tris--HCl at pH 8.0. Control digests of the isolated plasmids were performed with *NheI* and *BamHI*, each used at 0.25 U/µg plasmid DNA, for insert restriction, and additionally *EcoRI* with a restriction within the insert was used (all, MBI) before analyzing on 1% agarose gels by electrophoresis. Finally, sequencing using the primers "CMV-Profor" (5′-aaa tgg gcg gta ggc gtg-3′) and "EGFP-Nrev" (5′-cgt cgc cgt cca gct c-3′) confirmed the correct product (Sequiserve, Vaterstetten, Germany).

1.3. Transfection of HCT116 cells {#s0020}
=================================

The human colorectal carcinoma HCT116 cell line was purchased from ATCC (Teddington, Middlesex, UK). The cells were cultured at 37 °C in a 5.0% CO~2~-atmosphere (Heraeus Instruments GmbH, Osterode, Germany) in RPMI-1640 medium (Biowhittaker™) supplemented with 10% fetal calf serum (Lonza, Verviers, Belgium). Transfection with *p*EGFP-N1 and *p*hCL-EGFP was performed using X-treme GENE HP DNA transfection reagent (Roche Diagnostics, Mannheim, Germany) following the manufacturer׳s protocol.

1.4. MTT assays {#s0025}
===============

Cell proliferation rates and metabolic activity levels of transfected HCT116 cells were examined by a colorimetric assay in which the yellow 3-\[4, 5-dimethylthiazol-2-yl\]-2,5-diphenyltetrazolium bromide (MTT) is reduced to form purple formazan crystals by intracellular NAD(P)H-oxidoreductase. The assays were performed in duplicates and repeated at least twice as previously described [@bib8], and the reaction product was quantified at 595 nm with a Tecan GENios Reader (Tecan Deutschland GmbH, Crailsheim, Germany).

1.5. Lysate preparation, SDS-PAGE, and immunoblotting {#s0030}
=====================================================

Transfected HCT116 cells were used 24 h post-transfection, and whole cell lysates were prepared in PBS containing 0.2% Triton X-100 as described before [@bib9], normalized to equal amounts of protein and loaded onto 12.5% SDS-polyacrylamide gels (GE Healthcare, 80-1255-53) along with a PAGE ruler pre-stained protein ladder (Fermentas). After transfer onto nitrocellulose, blots were incubated with goat anti-human cathepsin L (1:500, Neuromics GT15049) and rabbit anti-human β-tubulin (1:1000, Abcam 6046-100) with HRP-coupled secondary antibodies used for subsequent visualization by enhanced chemi-luminescence onto CL-XPosure film (Pierce, through Perbio Science Europe, Bonn, Germany).

2. Results {#s0035}
==========

Cathepsin L has been shown to be mis-trafficked in HCT116 cells and to enter the nucleus as an unexpected scene of potential action [@bib1]. Nuclear cathepsin L is suggested to involve in regulation of cell cycle progression of HCT116 cells by accelerating S phase [@bib1]. Moreover, the vector *p*hCL-EGFP coding for EGFP-tagged cathepsin L was expressed in HCT116 cells and sorted to the nucleus \[[@bib1], Fig. 7D′\].

2.1. Construction of the *p*hCL-EGFP vector {#s0040}
-------------------------------------------

Vector construction was performed upon cloning of human cathepsin L from non-tumorigenic HaCaT keratinocytes and cDNA was inserted into the *p*EGFP-N1 vector (Clontech, Heidelberg, Germany), resulting in the fusion of sequences coding for cathepsin L and eGFP in *p*hCL-EGFP. The cloning strategy ([Fig. 1](#f0005){ref-type="fig"}) involved removal of the stop-codon at the 3′-end of cathepsin L cDNA, and introduced restriction sites for *NheI* and *BamHI* at the 5′- and 3′-ends, respectively, to ensure that the complete coding sequence was amplified. Removal of the stop-codon by *BamHI* digestion permitted further transcription once the gene was ligated in-frame into the suitable vector *p*EGFP-N1 to obtain mRNA coding for a fusion construct of cathepsin L and the marker protein enhanced GFP.

Transformed *E. coli* colonies with the cathepsin L sequence inserted into the EGFP-encoding vector were cultivated in kanamycin-containing LB medium, and plasmids were harvested from this broth of resistant bacteria. As an additional control of proper vector construction, the purified plasmids were digested with *NheI* and *BamHI* to gain the insert, and additionally with *EcoRI*, which cleaves once within the cathepsin L sequence. Therefore, after digest of cathepsin L-EGFP-containing plasmids, fragments with a length of 4700 bp, 760 bp, and 259 bp were expected. The preparations were analyzed by agarose gel electrophoresis, and three bands of the expected size were observed in the digests of *p*hCL-EGFP ([Fig. 2](#f0010){ref-type="fig"}).

Next, the plasmid *p*hCL-EGFP was sequenced from downstream (starting 5′) and upstream (starting 3′) in the vector ([Fig. 3](#f0015){ref-type="fig"}). Alignment of this cDNA sequence with the reported human cathepsin L sequence (preprocathepsin L precursor, *Homo sapiens*, accession number GenBank AAA66974.1) revealed 100% identity, confirming that cathepsin L-coding cDNA was inserted into the *p*EGFP-N1 vector as shown in the vector map of *p*hCL-EGFP ([Fig. 4](#f0020){ref-type="fig"}).

2.2. Transfection of HCT116 cells with *p*hCL-EGFP {#s0045}
==================================================

Sub-confluent cultures of HCT116 cells were transiently transfected with *p*hCL-EGFP yielding expression of full-length cathepsin L, which was co-localized with endogenous cathepsin L and also reached the nuclei (see Fig. 7D′ in [@bib1]). In addition, MTT assays were performed with non-transfected, *p*EGFP-N1-, and *p*hCL-EGFP-transfected HCT116 cells after 24 h. Data revealed that proliferation rates were not altered upon expression of enhanced GFP alone, while the MTT conversion rates were increased in HCT116 cells expressing hCL-EGFP chimeras ([Fig. 5](#f0025){ref-type="fig"}), although this increase did not reach significance over non-transfected controls.

2.3. Molecular forms of cathepsin L-EGFP chimeras translated in HCT116 cells {#s0050}
============================================================================

To identify the molecular forms of the cathepsin L-EGFP chimeras translated in HCT116 cells, immunoblotting was performed with whole cell Iysates of non-transfected cultures and with those expressing *p*EGFP-N1 or *p*hCL-EGFP, respectively. The expected molecular forms of cathepsin L were detected in all samples, i.e. the pro-form as well as the single chain (SC) and heavy chain (HC) of the two-chain form of the protease. Lysates of *p*hCL-EGFP-transfected HCT116 cells featured an additional band at 65 kDa that was recognized by cathepsin L-specific antibodies ([Fig. 6](#f0030){ref-type="fig"}), and which was absent from non-transfected cells or those transfected with the empty vector *p*EGFP-N1. The data indicates that the band at 65 kDa is representative of the hCL-EGFP chimeric protein which was stable for 24 h in HCT116 cells because no degradation bands could be observed in immunoblots with cathepsin L-specific antibodies ([Fig. 6](#f0030){ref-type="fig"}).

Appendix A. Supplementary material {#s0060}
==================================
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![Scheme of specific amplification primers and expected amplicon. Forward and reverse primers for gene-specific amplification of cathepsin L are indicated in red and their amplicon is highlighted in green. Cleavage sites of *NheI* and *BamHI* are indicated by arrows. Numbers denote the length of the gene.](gr1){#f0005}

![Agarose gel of control digest of *p*hCL-EGFP. Agarose gel of harvested plasmid *p*hCL-EGFP from three different clones after colony PCR and digestion with *NheI*, *BamHI*, and *EcoRI* is depicted. The expected fragments for cathepsin L-inserts and linearized vector with a length of 4700 bp, 760 bp, and 259 bp were detected after digest (arrowheads).](gr2){#f0010}

![Partial sequence of *p*hCL-EGFP. Nucleotide sequence of insert region of *p*hCL-EGFP as revealed by up- and down-stream sequencing reactions is depicted. The cathepsin L-coding sequence is highlighted in light green, sequences of the surrounding vector are labeled in red, start-codons ATG of cathepsin L and EGFP, respectively, are underlined, primers are marked in dark green, the cleavage site of *NheI* is shown in black, the restriction site of *BamHI* is marked in pink, and the *EcoRI* site in grey, while the spacer sequence between cathepsin L and EGFP is color-coded in dark blue.](gr3){#f0015}

![Vector map of *p*hCL-EGFP. Scheme of the 5.7-kb-vector *p*hCL-EGFP coding for full-length cathepsin L-EGFP chimeric protein is depicted. Note that cathepsin L was cloned into the multiple cloning site (MCS) of the *p*EGFP-N1 vector (Clontech) using *NheI* and *BamHI* as indicated. Additionally the restriction site for *EcoRI* within the cDNA sequence that was used for control digests is marked (arrow). Numbers denote the size of full-length cathepsin L-coding cDNA and that of the expected fragments after control digest.](gr4){#f0020}

![Effects of cathepsin L-EGFP expression on proliferation and metabolic activity of HCT116 cells. Quantitative analyses of cell numbers and metabolic activities by MTT assays were performed with non-transfected HCT116 cells in comparison to cells analyzed 24 h after transfection with *p*EGFP and *p*hCL-EGFP, as indicated. Values are given as means±standard deviations of at least two independent experiments.](gr5){#f0025}

![Molecular forms and integrity of transiently expressed cathepsin L-EGFP chimeras in HCT116 cells. Immunoblot analyses were conducted with whole cell lysates of HCT116 cells transiently expressing *p*EGFP-N1 and *p*hCL-EGFP as indicated, in comparison to non-transfected controls. Visualization of bands immunoreactive with cathepsin L-specific antibodies (A) was performed by enhanced chemi-luminescence. Note that the chimeric protein CL-EGFP was detectable at approx. 65 kDa as expected for the intact protein. In addition, all expected molecular forms of cathepsin L were detected with anti-cathepsin L-specific antibodies (pro, SC, and HC). ß-Tubulin was used as a loading control (B). Molecular mass markers are indicated in the left margins.](gr6){#f0030}

[^1]: Present address: EMBL, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
